miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia

Citations Over TimeTop 10% of 2016 papers

Abstract

MicroRNAs are subject to precise regulation and have key roles in tumorigenesis. In contrast to the oncogenic role of miR-22 reported in myelodysplastic syndrome (MDS) and breast cancer, here we show that miR-22 is an essential anti-tumour gatekeeper in de novo acute myeloid leukaemia (AML) where it is significantly downregulated. Forced expression of miR-22 significantly suppresses leukaemic cell viability and growth in vitro, and substantially inhibits leukaemia development and maintenance in vivo. Mechanistically, miR-22 targets multiple oncogenes, including CRTC1, FLT3 and MYCBP, and thus represses the CREB and MYC pathways. The downregulation of miR-22 in AML is caused by TET1/GFI1/EZH2/SIN3A-mediated epigenetic repression and/or DNA copy-number loss. Furthermore, nanoparticles carrying miR-22 oligos significantly inhibit leukaemia progression in vivo. Together, our study uncovers a TET1/GFI1/EZH2/SIN3A/miR-22/CREB-MYC signalling circuit and thereby provides insights into epigenetic/genetic mechanisms underlying the pathogenesis of AML, and also highlights the clinical potential of miR-22-based AML therapy.

Related Papers

• → EZH2 as a potential target in cancer therapy(2014)88 cited
• → Two systems of glucose repression of the GAL1 promoter in Saccharomyces cerevisiae.(1990)180 cited
• → Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2(2012)26 cited
• → Molecular Basis of Transient Repression of β-Galactosidase in Escherichia coli(1969)34 cited
• → Abstract 2011: Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A against non-small cell lung cancer cells(2011)